Safety and Effectiveness of CPI-1189 in HIV-Infected Males on Combination Anti-HIV Drug Therapy

Completed · Phase 1

Conditions studied: AIDS Dementia Complex, HIV Infections

In brief

The purpose of this study is to see if it is safe to give multiple doses of CPI-1189 to HIV-infected, otherwise healthy, males. The study will also look at how CPI-1189 affects the levels of HIV, T cells (cells in the body that help fight infection), and three anti-HIV drugs (zidovudine, lamivudine, and indinavir) in the blood. Advanced HIV infection can cause AIDS dementia (brain damage due to HIV leading to losses of memory and muscle control). CPI-1189 may be able to postpone AIDS dementia or slow it down.

Key facts

Study ID

NCT00002209

Run by

Centaur Pharmaceuticals

People needed

48

Last updated by the study team

2005-06-24

Who can join

Age: 18 and older, up to 50. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• You may be eligible for this study if you:
• Are an HIV-positive man who is otherwise in good health.
• Are 18-50 years old.
• Have a CD4 count of 75-500 cells/mm3.
• Are currently taking zidovudine (ZDV), lamivudine (3TC), and indinavir (IDV).

Where it is running

• MDS Harris — Phoenix, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.